Strong Analyst Sentiment on TScan Therapeutics (TCRX) Amid Ongoing Momentum in Cell Therapy Space
As of March 19, 2026, analysts maintain a strong sentiment regarding TScan Therapeutics, Inc. (TCRX).
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lynx1 Capital Management Weston Nichols | 8,019,148 | $8,099,339 | 1.28% | |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,564,290 | $5,619,933 | +7% | 0.18% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,784,792 | $2,812,640 | 0.02% | |
| 4. | Millennium Management Israel Englander | 1,460,285 | $1,474,888 | +262% | 0% |
| 5. | Renaissance Technologies Jim Simons | 1,364,783 | $1,378,431 | +20% | 0% |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.90 | 6,232 | $5,601.94 | 8,019,148 | 2025-12-23 | Filing | |
| $0.90 | 75,500 | $67,950.00 | 8,012,916 | 2025-12-22 | Filing | |
| $0.90 | 80,069 | $71,974.02 | 7,937,416 | 2025-12-19 | Filing | |
| $1.20 | 1,200,000 | $1,440,000.00 | 7,946,141 | 2025-05-20 | Filing | |
| $1.20 | 1,388,794 | $1,666,552.80 | 6,746,141 | 2025-05-19 | Filing |
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $5.78 | 164,686 | $952,115.64 | 4,716 | 2024-08-23 | Filing | |
| $2.51 | 400 | $1,003.00 | 5,224,600 | 2023-05-31 | Filing | |
| $2.52 | 15,000 | $37,801.50 | 5,225,000 | 2023-05-31 | Filing | |
| $2.51 | 10,000 | $25,148.00 | 5,240,000 | 2023-05-31 | Filing |
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,154,256 | $2,175,799 | 0% | |
| 2. | 1,840,952 | $1,859,362 | 0% | |
| 3. | 1,245,504 | $1,257,959 | 0.2% | |
| 4. | 918,020 | $927,200 | 0% | |
| 5. | 808,356 | $816,440 | 0% |